Decreased expression of DUSP4 is associated with liver and lung metastases in colorectal cancer

Medical Oncology

Volumn 30, Issue 3, 2013, Pages

  Saigusa, Susumu ^a   Inoue, Yasuhiro ^a   Tanaka, Koji ^a   Toiyama, Yuji ^a   Okugawa, Yoshinaga ^a   Shimura, Tadanobu ^a   Hiro, Junichiro ^a   Uchida, Keiichi ^a   Mohri, Yasuhiko ^a   Kusunoki, Masato ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Colorectal cancer; Distant metastasis; DUSP4; Tumor suppressor

Indexed keywords

DUAL SPECIFICITY PHOSPHATASE 4; K RAS PROTEIN; PHOSPHATASE; UNCLASSIFIED DRUG; DUAL SPECIFICITY PHOSPHATASE; DUSP4 PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE; ONCOPROTEIN; RAS PROTEIN;

AGED; ARTICLE; CANCER CELL; CODON; COLORECTAL CANCER; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; TUMOR VOLUME; COLORECTAL TUMOR; GENETICS; INTESTINE MUCOSA; LIVER TUMOR; LUNG TUMOR; METASTASIS; MUTATION; PATHOLOGY; PROGNOSIS; SECONDARY; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

AGED; COLORECTAL NEOPLASMS; DUAL-SPECIFICITY PHOSPHATASES; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; INTESTINAL MUCOSA; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHATASES; MUTATION; NEOPLASM METASTASIS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 84892424859     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0620-x     Document Type: Article

References (30)

1. Weitz J, Koch M, Debus J, et al. Colorectal cancer. Lancet. 2005;365:153-65.
2. Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget. 2010;1:651-61.
3. Lin H, Balic M, Zheng S, et al. Disseminated and circulating tumor cells: role in effective cancer management. Crit Rev Oncol Hematol. 2011;77:1-11.
4. Wirtz D, Konstantopoulos K, Searson PC. The physics of cancer: the role of physical interactions and mechanical forces in metastasis. Nat Rev Cancer. 2011;11:512-22.
5. Keyse SM. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev. 2008;27:253-61.
6. Shen WH, Wang J, Wu J, et al. Mitogen-activated protein kinase phosphatase 2: a novel transcription target of p53 in apoptosis. Cancer Res. 2006;66:6033-9.
7. Cadalbert L, Sloss CM, Cameron P, Plevin R. Conditional expression of MAP kinase phosphatase-2 protects against genotoxic stress-induced apoptosis by binding and selective dephosphorylation of nuclear activated c-jun N-terminal kinase. Cell Signal. 2005;17:1254-64.
8. Cadalbert LC, Sloss CM, Cunningham MR, et al. Differential regulation of MAP kinase activation by a novel splice variant of human MAP kinase phosphatase-2. Cell Signal. 2010;22:357-65.
9. Armes JE, Hammet F, de Silva M, et al. Candidate tumor-suppressor genes on chromosome arm 8p in early-onset and highgrade breast cancers. Oncogene. 2004;23:5697-702.
10. Chitale D, Gong Y, Taylor BS, et al. An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene. 2009;28:2773-83.
11. Waha A, Felsberg J, Hartmann W, et al. Epigenetic downregulation of mitogen-activated protein kinase phosphatase MKP-2 relieves its growth suppressive activity in glioma cells. Cancer Res. 2010;70:1689-99.
12. Hasegawa T, Enomoto A, Kato T, et al. Roles of induced expression of MAPK phosphatase-2 in tumor development in RET-MEN2A transgenic mice. Oncogene. 2008;27:5684-95.
13. Lawan A, Al-Harthi S, Cadalbert L, et al. Deletion of the dual specific phosphatase-4 (DUSP-4) gene reveals an essential nonredundant role for MAP kinase phosphatase-2 (MKP-2) in proliferation and cell survival. J Biol Chem. 2011;286:12933-43.
14. Wang HY, Cheng Z, Malbon CC. Overexpression of mitogenactivated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Lett. 2003;191:229-37.
15. Gaedcke J, Grade M, Jung K, et al. Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas. Genes Chromosomes Cancer. 2010;49:1024-34.
16. Groschl B, Bettstetter M, Giedl C, et al. Expression of the MAP kinase phosphatase DUSP4 is associated with microsatellite instability in colorectal cancer (CRC) and causes increased cell proliferation. Int J Cancer. 2013;132:1537-46.
17. Balko JM, Cook RS, Vaught DB, et al. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat Med. 2012;18:1052-9.
18. Brink M, de Goeij AF, Weijenberg MP, et al. K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis. 2003;24:703-10.
19. Baldus SE, Schaefer KL, Engers R, et al. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res. 2010;16:790-9.
20. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66:3992-5.
21. Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26: 374-9.
22. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757-65.
23. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626-34.
24. Britson JS, Barton F, Balko JM, Black EP. Deregulation of DUSP activity in EGFR-mutant lung cancer cell lines contributes to sustained ERK1/2 signaling. Biochem Biophys Res Commun. 2009;390:849-54.
25. Cagnol S, Rivard N. Oncogenic KRAS and BRAF activation of the MEK/ERK signaling pathway promotes expression of dualspecificity phosphatase 4 (DUSP4/MKP2) resulting in nuclear ERK1/2 inhibition. Oncogene. 2012;32:564-76.
26. Saigusa S, Inoue Y, Tanaka K, et al. Significant correlation between LKB1 and LGR5 gene expression and the association with poor recurrence-free survival in rectal cancer after preoperative chemoradiotherapy. J Cancer Res Clin Oncol. 2013;139:131-8.
27. Yip-Schneider MT, Lin A, Marshall MS. Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2. Biochem Biophys Res Commun. 2001;280:992-7.
28. Teutschbein J, Haydn JM, Samans B, et al. Gene expression analysis after receptor tyrosine kinase activation reveals new potential melanoma proteins. BMC Cancer. 2010;10:386.
29. Sieben NL, Oosting J, Flanagan AM, et al. Differential gene expression in ovarian tumors reveals Dusp 4 and Serpina 5 as key regulators for benign behavior of serous borderline tumors. J Clin Oncol. 2005;23:7257-64.
30. Fernandez-Rozadilla C, Cazier JB, Tomlinson IP, et al. A colorectal cancer genome-wide association study in a Spanish cohort identifies two variants associated with colorectal cancer risk at 1p33 and 8p12. BMC Genomics. 2013;14:55.